BCBS Minnesota coverage for Zepbound (Osa)

Employer / Commercial Insurance

Depends on your plan's benefit

Expanded indications must NOT be restricted from coverage under the patient's pharmacy benefit.

What you need to qualify

Age 18 and older
BMI of 30 or higher
Prescribed by or in consultation with a specialist
Diagnosed obstructive sleep apnea (AHI of 15 or higher)

Qualification pathways

You can qualify through any one of these.

OSA with Obesity — Initial Approval

All of:

Diagnosis of obstructive sleep apnea (OSA)
Expanded indications are NOT restricted from coverage under the patient's pharmacy benefit
Patient has had a polysomnography (PSG) or home sleep apnea test
Patient has an apnea hypopnea index (AHI) >= 15 events/hour from baseline (prior to initiation of pharmacotherapy)
Requested agent is Zepbound
Patient has a BMI >= 30 kg/m2
Patient does NOT have craniofacial abnormalities that may affect breathing
Patient does NOT have a diagnosis of Central or Mixed Sleep Apnea with mixed or central apneas/hypopneas >= 50%
Patient does NOT have a diagnosis of Cheyne Stokes Respiration
Patient does NOT have a diagnosis of Obesity Hypoventilation Syndrome or daytime hypercapnia
Prescriber is a specialist (e.g., pulmonologist, sleep specialist) or has consulted with a specialist
Patient will NOT use the requested agent in combination with another weight loss agent
Patient is currently on and will continue weight management regimen (low-calorie diet, increased physical activity, behavioral modifications)
Patient will NOT use the requested agent in combination with another GLP-1 receptor agonist
Patient does NOT have any FDA labeled contraindications
Patient has tried and failed at least three formulary alternatives OR prescriber indicates alternatives are contraindicated, likely less effective, or likely to cause adverse reaction

Documentation to bring

Medical records documenting diagnosis of obstructive sleep apnea (OSA)
Results of polysomnography (PSG) or home sleep apnea test showing AHI >= 15 events/hour from baseline (prior to pharmacotherapy initiation)
Documentation of BMI >= 30 kg/m2
Documentation ruling out: craniofacial abnormalities affecting breathing, Central or Mixed Sleep Apnea with >= 50% central/mixed apneas-hypopneas, Cheyne Stokes Respiration, Obesity Hypoventilation Syndrome or daytime hypercapnia
Documentation of specialist involvement (pulmonologist or sleep specialist) or consultation
Documentation of formulary alternatives tried and failed (at least 3), or clinical reason alternatives are contraindicated/less effective/harmful

Approval and renewal

Initial approval: 12 months
Renewal: every 12 months
To renew, the plan looks for At renewal: patient must have had clinical benefit with the requested agent (e.g., reduction in AHI, decrease in Epworth Sleepiness Scale). Specialist requirement is re-verified. AHI >= 15 threshold is NOT re-verified at renewal — only clinical benefit is required.

Not covered when

Craniofacial abnormalities that may affect breathing
Diagnosis of Central or Mixed Sleep Apnea with mixed or central apneas/hypopneas >= 50%
Diagnosis of Cheyne Stokes Respiration
Diagnosis of Obesity Hypoventilation Syndrome or daytime hypercapnia
Co-administration with another weight loss agent
Co-administration with another GLP-1 receptor agonist
Any FDA labeled contraindications
Expanded indications restricted from coverage under patient's pharmacy benefit

Policy note: PAP therapy trial is NOT required prior to approval — this is an expanded indication. The policy does not require that PAP therapy be tried or failed. OSA indication requires AHI >= 15 events/hour (moderate-to-severe OSA threshold) from baseline prior to pharmacotherapy initiation, confirmed by PSG or home sleep apnea test. Renewal requires clinical benefit (e.g., AHI reduction, Epworth Sleepiness Scale improvement) but does not re-require the baseline AHI >= 15 threshold. Managed by Prime Therapeutics.

Policy effective April 1, 2026 · verified June 5, 2026 · source: Pa policy